Small Dimension–Big Impact! Nanoparticle-Enhanced Non-Invasive and Intravascular Molecular Imaging of Atherosclerosis In Vivo

Extensive translational research has provided considerable progress regarding the understanding of atherosclerosis pathophysiology over the last decades. In contrast, implementation of molecular in vivo imaging remains highly limited. In that context, nanoparticles represent a useful tool. Their variable shape and composition assure biocompatibility and stability within the environment of intended use, while the possibility of conjugating different ligands as well as contrast dyes enable targeting of moieties of interest on a molecular level and visualization throughout various imaging modalities. These characteristics have been exploited by a number of preclinical research approaches aimed at advancing understanding of vascular atherosclerotic disease, in order to improve identification of high-risk lesions prior to oftentimes fatal thromboembolic events. Furthermore, the combination of these targeted nanoparticles with therapeutic agents offers the potential of site-targeted drug delivery with minimized systemic secondary effects. This review gives an overview of different groups of targeted nanoparticles, designed for in vivo molecular imaging of atherosclerosis as well as an outlook on potential combined diagnostic and therapeutic applications.

[1]  Wenli Chen,et al.  Construction of dual nanomedicines for the imaging and alleviation of atherosclerosis , 2020, Artificial cells, nanomedicine, and biotechnology.

[2]  Zhigang Wang,et al.  Polydopamine-modified dual-ligand nanoparticles as highly effective and targeted magnetic resonance/photoacoustic dual-modality thrombus imaging agents , 2019, International journal of nanomedicine.

[3]  Eloisa Arbustini,et al.  Relationship between coronary plaque morphology of the left anterior descending artery and 12 months clinical outcome: the CLIMA study. , 2019, European heart journal.

[4]  M. Bennett,et al.  Vascular smooth muscle cells in atherosclerosis , 2019, Nature Reviews Cardiology.

[5]  C. Alexiou,et al.  Plaque Permeability Assessed With DCE-MRI Associates With USPIO Uptake in Patients With Peripheral Artery Disease. , 2019, JACC. Cardiovascular imaging.

[6]  Eric D. Pressly,et al.  Assessment of Targeted Nanoparticle Assemblies for Atherosclerosis Imaging with Positron Emission Tomography and Potential for Clinical Translation. , 2019, ACS applied materials & interfaces.

[7]  L. Gutiérrez,et al.  Unambiguous detection of atherosclerosis using bioorthogonal nanomaterials. , 2019, Nanomedicine : nanotechnology, biology, and medicine.

[8]  N. Leeper,et al.  Nanoparticle Therapy for Vascular Diseases , 2019, Arteriosclerosis, thrombosis, and vascular biology.

[9]  E. Arbustini,et al.  Introductory editorial , 2019, Carbonates and Evaporites.

[10]  A. Levin Treating Disease at the RNA Level with Oligonucleotides. , 2019, The New England journal of medicine.

[11]  Seyed Mohammadali Dadfar,et al.  Iron oxide nanoparticles: Diagnostic, therapeutic and theranostic applications , 2019, Advanced drug delivery reviews.

[12]  J. Zamorano,et al.  Non-Invasive Detection of Extracellular Matrix Metalloproteinase Inducer EMMPRIN, a New Therapeutic Target against Atherosclerosis, Inhibited by Endothelial Nitric Oxide , 2018, International journal of molecular sciences.

[13]  Franca De Sarno,et al.  Emerging use of nanoparticles in diagnosis of atherosclerosis disease: A review , 2018 .

[14]  P. Libby,et al.  Plaque erosion: a new in vivo diagnosis and a potential major shift in the management of patients with acute coronary syndromes. , 2018, European heart journal.

[15]  C. Alexiou,et al.  Dextran-coated superparamagnetic iron oxide nanoparticles for magnetic resonance imaging: evaluation of size-dependent imaging properties, storage stability and safety , 2018, International journal of nanomedicine.

[16]  E. Boerwinkle,et al.  CD163+ macrophages promote angiogenesis and vascular permeability accompanied by inflammation in atherosclerosis , 2018, The Journal of clinical investigation.

[17]  R. Dixon,et al.  Magnetic Resonance Imaging of Atherosclerotic Plaque at Clinically Relevant Field Strengths (1T) by Targeting the Integrin α4β1 , 2018, Scientific Reports.

[18]  S. Thom,et al.  Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial , 2018, The Lancet.

[19]  Ashley F. Stein,et al.  Quantitative intravascular biological fluorescence-ultrasound imaging of coronary and peripheral arteries in vivo , 2017, European heart journal cardiovascular Imaging.

[20]  P. Serruys,et al.  Intravascular multimodality imaging: feasibility and role in the evaluation of coronary plaque pathology , 2017, European heart journal cardiovascular Imaging.

[21]  P. Libby,et al.  Atheroma Susceptible to Thrombosis Exhibit Impaired Endothelial Permeability In Vivo as Assessed by Nanoparticle-Based Fluorescence Molecular Imaging , 2017, Circulation. Cardiovascular imaging.

[22]  R. Virmani,et al.  Linking Hemorrhage, Angiogenesis, Macrophages, and Iron Metabolism in Atherosclerotic Vascular Diseases , 2017, Arteriosclerosis, thrombosis, and vascular biology.

[23]  P. Serruys,et al.  Hybrid intravascular imaging: recent advances, technical considerations, and current applications in the study of plaque pathophysiology , 2017, European heart journal.

[24]  F. Jaffer,et al.  Molecular Imaging of Atherosclerosis: a Clinical Focus , 2017, Current Cardiovascular Imaging Reports.

[25]  B. Bettencourt,et al.  A Highly Durable RNAi Therapeutic Inhibitor of PCSK9 , 2017, The New England journal of medicine.

[26]  K. Hodivala-Dilke,et al.  αvβ3 Integrin and tumour blood vessels-learning from the past to shape the future. , 2016, Current opinion in cell biology.

[27]  Satoshi Yasuda,et al.  Pathology of coronary atherosclerosis and thrombosis. , 2016, Cardiovascular diagnosis and therapy.

[28]  P. Woodard,et al.  Natriuretic Peptide Receptor-C is Up-Regulated in the Intima of Advanced Carotid Artery Atherosclerosis. , 2016, Journal of medical & surgical pathology.

[29]  Kristofer J. Thurecht,et al.  Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date , 2016, Pharmaceutical Research.

[30]  Renu Virmani,et al.  Acute coronary syndromes without coronary plaque rupture , 2016, Nature Reviews Cardiology.

[31]  Aloke V. Finn,et al.  Pathophysiology of native coronary, vein graft, and in-stent atherosclerosis , 2016, Nature Reviews Cardiology.

[32]  P. Serruys,et al.  Vulnerable plaque detection: an unrealistic quest or a feasible objective with a clinical value? , 2016, Heart.

[33]  E. Edelman,et al.  Intravascular fibrin molecular imaging improves the detection of unhealed stents assessed by optical coherence tomography in vivo , 2015, European heart journal.

[34]  J. Egido,et al.  Targeted gold-coated iron oxide nanoparticles for CD163 detection in atherosclerosis by MRI , 2015, Scientific Reports.

[35]  Bernadette A. Thomas,et al.  Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 , 2015, The Lancet.

[36]  P. Serruys,et al.  Near-infrared spectroscopy predicts cardiovascular outcome in patients with coronary artery disease. , 2014, Journal of the American College of Cardiology.

[37]  D. McPherson,et al.  Nitric oxide pretreatment enhances atheroma component highlighting in vivo with intercellular adhesion molecule-1-targeted echogenic liposomes. , 2014, Ultrasound in medicine & biology.

[38]  Kai Jiang,et al.  Dual-Modal Magnetic Resonance and Fluorescence Imaging of Atherosclerotic Plaques in Vivo Using VCAM-1 Targeted Tobacco Mosaic Virus , 2014, Nano letters.

[39]  R. Weissleder,et al.  Imaging macrophages with nanoparticles. , 2014, Nature materials.

[40]  B. Bettencourt,et al.  Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial , 2014, The Lancet.

[41]  G. Norata,et al.  LOX-1, OxLDL, and Atherosclerosis , 2013, Mediators of inflammation.

[42]  Stanislav Emelianov,et al.  In vivo intravascular ultrasound-guided photoacoustic imaging of lipid in plaques using an animal model of atherosclerosis. , 2012, Ultrasound in medicine & biology.

[43]  P. Libby Inflammation in Atherosclerosis , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[44]  Michail I. Papafaklis,et al.  Prediction of Progression of Coronary Artery Disease and Clinical Outcomes Using Vascular Profiling of Endothelial Shear Stress and Arterial Plaque Characteristics: The PREDICTION Study , 2012, Circulation.

[45]  S. Harris,et al.  OxLDL-targeted iron oxide nanoparticles for in vivo MRI detection of perivascular carotid collar induced atherosclerotic lesions in ApoE-deficient mice , 2012, Journal of Lipid Research.

[46]  P. Libby,et al.  Two-dimensional intravascular near-infrared fluorescence molecular imaging of inflammation in atherosclerosis and stent-induced vascular injury. , 2011, Journal of the American College of Cardiology.

[47]  P. Libby,et al.  Indocyanine Green Enables Near-Infrared Fluorescence Imaging of Lipid-Rich, Inflamed Atherosclerotic Plaques , 2011, Science Translational Medicine.

[48]  Akiko Maehara,et al.  A prospective natural-history study of coronary atherosclerosis. , 2011, The New England journal of medicine.

[49]  M. Odenthal,et al.  Profilin-1 Is Expressed in Human Atherosclerotic Plaques and Induces Atherogenic Effects on Vascular Smooth Muscle Cells , 2010, PloS one.

[50]  Z. Fayad,et al.  Annexin A5-functionalized bimodal nanoparticles for MRI and fluorescence imaging of atherosclerotic plaques. , 2010, Bioconjugate chemistry.

[51]  T. Pellegrino,et al.  From iron oxide nanoparticles towards advanced iron-based inorganic materials designed for biomedical applications. , 2010, Pharmacological research.

[52]  C. Meyer,et al.  Molecular Imaging of Atherosclerotic Plaques Targeted to Oxidized LDL Receptor LOX-1 by SPECT/CT and Magnetic Resonance , 2010, Circulation. Cardiovascular imaging.

[53]  Konstantin Sokolov,et al.  Plasmonic intravascular photoacoustic imaging for detection of macrophages in atherosclerotic plaques. , 2009, Nano letters.

[54]  Claudia Calcagno,et al.  Nanocrystal core high-density lipoproteins: a multimodality contrast agent platform. , 2008, Nano letters.

[55]  Ralph Weissleder,et al.  Nanoparticle PET-CT Imaging of Macrophages in Inflammatory Atherosclerosis , 2008, Circulation.

[56]  Elena Galkina,et al.  Vascular adhesion molecules in atherosclerosis. , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[57]  Ralph Weissleder,et al.  Noninvasive Vascular Cell Adhesion Molecule-1 Imaging Identifies Inflammatory Activation of Cells in Atherosclerosis , 2006, Circulation.

[58]  Marc Sirol,et al.  Neovascularization in Human Atherosclerosis , 2006, Circulation.

[59]  R. Weissleder,et al.  Cellular Imaging of Inflammation in Atherosclerosis Using Magnetofluorescent Nanomaterials , 2006, Molecular imaging.

[60]  J. Spratt,et al.  Plaque stabilisation by systemic and local drug administration , 2004, Heart.

[61]  Samuel A. Wickline,et al.  Molecular Imaging of Angiogenesis in Early-Stage Atherosclerosis With &agr;v&bgr;3-Integrin–Targeted Nanoparticles , 2003 .

[62]  R. Virmani,et al.  Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[63]  Jiwon Kim,et al.  Thrombin-activatable fluorescent peptide incorporated gold nanoparticles for dual optical/computed tomography thrombus imaging. , 2018, Biomaterials.